Skip to main content

Table 3 KRAS mutation frequencies observed in carcinoma

From: KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay

  primary carcinoma recurrent carcinoma carcinoma total
  n mutated % mutated n mutated % mutated n mutated % mutated
  270 43 15.93 82 5 6.10 352 48 13.64
histotype          
serous 177 17 9.60 69 4 5.80 246 21 8.54
endometroid 34 4 11.76 5 0 0.00 39 4 10.26
mucinous 25 15 60.00 5 1 20.00 30 16 53.33
clear cell 19 5 26.32 2 0 0.00 21 5 23.81
undifferent. 10 0 0.00 1 0 0.00 11 0 0.00
unknown 5 2 40.00     5 2 40.00
age          
≤ 50 72 16 22.22 31 4 12.90 103 20 19.42
> 50 198 27 13.64 51 1 1.96 249 28 11.24
grading          
1 33 17 51.52 7 0 0.00 40 17 42.50
2 90 14 15.56 27 4 14.81 117 18 15.38
3 141 12 8.51 46 1 2.17 187 13 6.95
4 1 0 0.00 0 0 0.00 1 0 0.00
unknown 5 0 0.00 2 0 0.00 7 0 0.00
FIGO stage          
1 65 17 26.15 9 0 0.00 74 17 22.97
2 31 5 16.13 8 0 0.00 39 5 12.82
3 145 17 11.72 48 4 8.33 193 21 10.88
4 28 4 14.29 13 1 7.69 41 5 12.20
unknown 1 0 0.00 4 0 0.00 5 0 0.00
pN          
0 104 17 16.35 19 0 0.00 123 17 13.82
1 67 7 10.45 28 4 14.29 95 11 11.58
x 99 19 19.19 35 1 2.86 134 20 14.93